Retatrutide
$190.00 Regular Price
$170.00Sale Price
Retatrutide is an investigational triple-agonist peptide (GLP-1, GIP, and glucagon receptor agonist) designed for obesity and type 2 diabetes treatment. Clinical trials (Phase 2/3) showed high efficacy, with participants losing up to 28.7% of body weight over 68 weeks, along with significant improvements in metabolic health.
Mechanism: As a "triple agonist," it acts on three receptors: GLP-1 (appetite suppression), GIP (metabolic flexibility), and Glucagon (increased energy expenditure).
Weight Loss Efficacy: Studies showed a 26.4%–28.7% weight reduction over 68 weeks, notably higher than existing single or dual-agonist therapies.
Administration:
It is designed as a once-weekly subcutaneous injection.
